Skip to content
value.today

Personal Genome Diagnostics Inc.

🇺🇸 Baltimore, Maryland, USABiotechnologyFounded 2010
Total raised
$193 M
6 rounds on record
Latest round
$98 M
Feb 2021
First round on record
Mar 2014
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Personal Genome Diagnostics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2021$98 MNo. 6$50 to $250 million

Personal Genome Diagnostics Inc.: Raise no. 6, Feb 2021

Investors in this round

38 investors had bought by the notice of Feb 23, 2021: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$98 M of $98 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jack A. Crowley · Executive Officer
  • Megan A. Bailey · Executive Officer, Director
  • Samuel A. Anguioli · Executive Officer
  • Scott A. Gotshall · Executive Officer
  • James A. LaFrance · Director
  • Justin A. Klein · Director
  • Kavita A. Patel · Director
  • Kevin A. Reidy · Director
  • Lily A. Li · Director
  • Luis A. Diaz, Jr. · Director
  • Victor A. Velculescu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Megan Bailey, Interim Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 23, 2021. Read the notice at the SEC.

equitySEC
May 2020$3 MNo. 5$2 to $10 million

Personal Genome Diagnostics Inc.: Raise no. 5, May 2020

Investors in this round

2 investors had bought by the notice of May 26, 2020: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $4 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jack A. Crowley · Executive Officer
  • Megan A. Bailey · Executive Officer
  • Sam A. Anguioli · Executive Officer
  • Garry A. Nicholson · Director
  • James A. LaFrance · Director
  • Jason A. Fuller · Director
  • Justin A. Klein · Director
  • Kavita A. Patel · Director
  • Luis A. Diaz, Jr. · Director
  • Victor A. Velculescu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Megan Bailey, Interim Chief Executive Officer. Source: SEC Form D, newest notice filed May 26, 2020. Read the notice at the SEC.

debt, optionsSEC
Jun 2019$5 MNo. 4$2 to $10 million

Personal Genome Diagnostics Inc.: Raise no. 4, Jun 2019

Investors in this round

1 investor had bought by the notice of Jun 24, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $20 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas A. Ward · Executive Officer, Director
  • Sam A. Anguioli · Executive Officer
  • Garry A. Nicholson · Director
  • Jack A. Crowley · Director
  • James A. LaFrance · Director
  • Jason A. Fuller · Director
  • Justin A. Klein · Director
  • Kavita A. Patel · Director
  • Luis A. Diaz, Jr. · Director
  • Victor A. Velculescu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Douglas Ward, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 24, 2019. Read the notice at the SEC.

debt, optionsSEC
Oct 2017$65 MNo. 3$50 to $250 million

Personal Genome Diagnostics Inc.: Raise no. 3, Oct 2017

Investors in this round

12 investors had bought by the notice of Oct 30, 2017: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$65 M of $112 M offered; $46 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Offer and sale of shares of preferred stock and the underlying shares of common stock issuable upon conversion thereof.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas A. Ward · Executive Officer, Director
  • Sam A. Anguioli · Executive Officer
  • William A. Stevens · Executive Officer
  • James A. LaFrance · Director
  • Justin A. Klein · Director
  • Luis A. Diaz, Jr. · Director
  • Victor A. Velculescu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Douglas Ward, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 30, 2017. Read the notice at the SEC.

equitySEC
Oct 2015$20 MNo. 2$10 to $50 million

Personal Genome Diagnostics Inc.: Raise no. 2, Oct 2015

Investors in this round

22 investors had bought by the notice of Nov 6, 2015: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $21 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Offer and sale of shares of preferred stock and the underlying shares of common stock issuable upon conversion thereof.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anthony A. Newton · Executive Officer
  • Jeff A. Boschwitz · Executive Officer
  • Luis A. Diaz, Jr. · Executive Officer, Director
  • Sam A. Anguioli · Executive Officer
  • Victor A. Velculescu · Executive Officer, Director
  • William A. Stevens · Executive Officer
  • Justin A. Klein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Victor Velculescu, Secretary. Source: SEC Form D, newest notice filed Nov 6, 2015. Read the notice at the SEC.

equitySEC
Mar 2014$2 MNo. 1$2 to $10 million

Personal Genome Diagnostics Inc.: Raise no. 1, Mar 2014

Investors in this round

2 investors had bought by the notice of Mar 17, 2014: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $4 M offered; $2 M still to sell
Smallest investment taken
$100,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$57,500
Finders' fees
none
Paid to its own people
$150,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Maryland

People named in the notice

  • Anthony J. Newton · Executive Officer
  • Luis A. Diaz, Jr. · Executive Officer, Director, Promoter
  • Victor A. Velculescu · Executive Officer, Director, Promoter
  • William J. Stevens · Executive Officer
  • Bert J. Vogelstein · Promoter
  • Kenneth W. Kinzler · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • John K. Dierkes (CRD 1629115) · broker-dealer Pickwick Capital Partners, LLC (CRD 130672) · White Plains, New YorkSold in MD

Signed by Luis A. Diaz, Jr., President. Source: SEC Form D, newest notice filed Mar 17, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Personal Genome Diagnostics Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2021).

    SEC Form D · Feb 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2021

That is all the official record says: Personal Genome Diagnostics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Personal Genome Diagnostics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 38 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Personal Genome Diagnostics Inc.
NameRoleNamed in
Jack A. CrowleyExecutive officerFeb 2021
Megan A. BaileyExecutive officerFeb 2021
Samuel A. AnguioliExecutive officerFeb 2021
Scott A. GotshallExecutive officerFeb 2021
Sam A. AnguioliExecutive officerMay 2020
Douglas A. WardExecutive officerJun 2019
William A. StevensExecutive officerOct 2017
Anthony A. NewtonExecutive officerNov 2015
Jeff A. BoschwitzExecutive officerNov 2015
Luis A. Diaz, Jr.Executive officerNov 2015
Victor A. VelculescuExecutive officerNov 2015
Anthony J. NewtonExecutive officerMar 2014
William J. StevensExecutive officerMar 2014
James A. LaFranceDirectorFeb 2021
Justin A. KleinDirectorFeb 2021
Kavita A. PatelDirectorFeb 2021
Kevin A. ReidyDirectorFeb 2021
Lily A. LiDirectorFeb 2021
Luis A. Diaz, Jr.DirectorFeb 2021
Megan A. BaileyDirectorFeb 2021
Victor A. VelculescuDirectorFeb 2021
Garry A. NicholsonDirectorMay 2020
Jason A. FullerDirectorMay 2020
Douglas A. WardDirectorJun 2019
Jack A. CrowleyDirectorJun 2019
Bert J. VogelsteinPromoterMar 2014
Kenneth W. KinzlerPromoterMar 2014
Luis A. Diaz, Jr.PromoterMar 2014
Victor A. VelculescuPromoterMar 2014